Research programme: rare genetic disorder therapeutics - Recursion Pharmaceuticals

Drug Profile

Research programme: rare genetic disorder therapeutics - Recursion Pharmaceuticals

Alternative Names: Inborn genetic disorder therapeutics - Recursion Pharmaceuticals; REC-0000355; REC-0000382; REC-0000716; REC-0001117; REC-0001202; REC-0001317; REC-0001571; REC-0001982

Latest Information Update: 27 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Recursion Pharmaceuticals
  • Class Antianaemics; Neuropsychotherapeutics; Skin disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inborn genetic disorders

Most Recent Events

  • 09 Oct 2017 Recursion Pharmaceuticals plans a clinical trial for Inborn genetic disorders in 2018
  • 28 Jun 2017 Recursion Pharmaceuticals announces intention to submit IND application to the US FDA for Inborn genetic disorders
  • 11 Mar 2015 Preclinical trials in Inborn genetic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top